Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification

被引:0
|
作者
Riemenschneider, MJ
Büschges, R
Wolter, M
Reifenberger, J
Boström, J
Kraus, JA
Schlegel, U
Reifenberger, G
机构
[1] Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany
[2] Univ Bonn, Med Ctr, Dept Neurosurg, D-53105 Bonn, Germany
[3] Univ Bonn, Med Ctr, Dept Neurol, D-53105 Bonn, Germany
[4] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously reported on the amplification and overexpression of the MDM2 proto-oncogene in a subset of malignant gliomas without TP53 mutation (G. Reifenberger et al., Cancer Res., 53: 2736-2739, 1993). Here, we show that the MDM4 (MDMX) gene located on 1q32 is a further target for amplification in malignant gliomas. MDM4 codes for a Mdm2-related protein that can bind to p53 and inhibits p53-mediated transcriptional transactivation. We investigated a series of 208 gliomas (106 glioblastomas, 46 anaplastic gliomas, and 56 low-grade gliomas) and identified 5 tumors (4 glioblastomas and 1 anaplastic oligodendroglioma) with MDM4 amplification and overexpression. Several other genes from 1q32 were found to be coamplified with MDM4, such as GAC1 in five tumors, REN in four tumors, and RBBP5 in three tumors. Additional analyses revealed that the malignant gliomas with MDM4 amplification and overexpression carried neither mutations in conserved regions of the TP53 gene nor amplification of the MDM2 gene. Taken together, our data indicate that amplification and overexpression of MDM4 is a novel molecular mechanism by which a small fraction of human malignant gliomas escapes p53-dependent growth control.
引用
收藏
页码:6091 / 6096
页数:6
相关论文
共 50 条
  • [41] Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
    Wang, Xiaoxuan
    Yamamoto, Yoshiyuki
    Imanishi, Mamiko
    Zhang, Xiaochen
    Sato, Masashi
    Sugaya, Akinori
    Hirose, Mitsuaki
    Endo, Shinji
    Natori, Yukikazu
    Moriwaki, Toshikazu
    Yamato, Kenji
    Hyodo, Ichinosuke
    ONCOLOGY LETTERS, 2021, 22 (01)
  • [42] Association between TP53, MDM2 and NQO1 gene polymorphisms and viral load among women with human papillomavirus
    AlBosale, A. H.
    Mashkina, E., V
    VAVILOVSKII ZHURNAL GENETIKI I SELEKTSII, 2022, 26 (01): : 59 - 64
  • [43] TP53 and MDM2 Gene Polymorphisms, Gene-Gene Interaction, and Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis
    Peng, Qiliu
    Lao, Xianjun
    Chen, Zhiping
    Lai, Hao
    Deng, Yan
    Wang, Jian
    Mo, Cuiju
    Sui, Jingzhe
    Wu, Junrong
    Zhai, Limin
    Yang, Shi
    Qin, Xue
    Li, Shan
    PLOS ONE, 2013, 8 (12):
  • [44] Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT
    El-Deiry, Wafik S.
    Horowitch, Brooke
    Lou, Emil
    Subbiah, Vivek
    Carneiro, Benedito A.
    Safran, Howard
    Gokaslan, Ziya L.
    Sobol, Robert W.
    Mani, Sendurai A.
    Lawler, Sean E.
    Chen, Clark C.
    Wong, Eric T.
    Kurzrock, Razelle
    Xiu, Joanne
    Elliott, Andrew
    Capelletti, Marzia
    Ressler, Steven
    Vanderwalde, Ari M.
    Nabhan, Chadi
    Spetzler, David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias
    Nishida, Yuki
    Ishizawa, Jo
    Ayoub, Edward
    Montoya, Rafael Heinz
    Ruvolo, Vivian
    Kojima, Kensuke
    Daver, Naval
    Lesegretain, Arnaud
    Shacham, Sharon
    Andreeff, Michael
    BLOOD, 2020, 136
  • [46] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey, I
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5236 - 5247
  • [47] Malignant epithelioid neoplasm with GLI1 gene rearrangement (PANX3::GLI1 transcript) and MDM2 gene amplification
    Konovalov, Dmitry
    Sharlai, Anastasia
    Panferova, Agnesa
    Korobova, Daria
    Rogozhin, Dmitrii
    Druy, Alexander
    VIRCHOWS ARCHIV, 2024,
  • [48] CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
    Saba, Karim H.
    Difilippo, Valeria
    Styring, Emelie
    Nilsson, Jenny
    Magnusson, Linda
    van den Bos, Hilda
    Wardenaar, Rene
    Spierings, Diana C. J.
    Foijer, Floris
    Nathrath, Michaela
    de Flon, Felix Haglund
    Baumhoer, Daniel
    Nord, Karolin H.
    NPJ GENOMIC MEDICINE, 2024, 9 (01)
  • [49] Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation
    Daniele Bergamaschi
    Yardena Samuels
    Shan Zhong
    Xin Lu
    Oncogene, 2005, 24 : 3836 - 3841
  • [50] Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation
    Bergamaschi, D
    Samuels, Y
    Zhong, S
    Lu, X
    ONCOGENE, 2005, 24 (23) : 3836 - 3841